- /
- Supported exchanges
- / US
- / MRKR.NASDAQ
Marker Therapeutics Inc (MRKR NASDAQ) stock market data APIs
Marker Therapeutics Inc Financial Data Overview
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Marker Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Marker Therapeutics Inc data using free add-ons & libraries
Get Marker Therapeutics Inc Fundamental Data
Marker Therapeutics Inc Fundamental data includes:
- Net Revenue: 3 547 K
- EBITDA: -11 792 272
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-19
- EPS/Forecast: -0.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Marker Therapeutics Inc News
New
Exploring 3 High Growth Tech Stocks in the US Market
The United States market has remained flat over the last week, yet it has shown a robust 28% increase over the past year with earnings expected to grow by 16% annually. In such an environment, identif...
High Growth Tech Stocks In US With Promising Potential
In the last week, the United States market has stayed flat, yet it has experienced a significant rise of 28% over the past 12 months, with earnings expected to grow by 16% per annum in the coming year...
Exploring High Growth Tech Stocks in the US Market
The United States market has shown a mixed performance recently, remaining flat over the last week but achieving a substantial 29% increase over the past year with earnings projected to grow by 16% an...
Exploring Three High Growth Tech Stocks In The US Market
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of ro...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.